Fibrotic Diseases Treatment Market
完整報告名稱與涵蓋範圍
Fibrotic Diseases Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Organ Transplantation, Oxygen Therapy, and Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, and Others), End User, Distribution Channel, By Region, And By Segment Forecasts, 2024-2031
報告摘要
The Fibrotic Diseases Treatment Market on a global scale was estimated at USD 3.57 billion in 2023 and is set to attain USD 5.40 billion by 2031, with a projected CAGR of 5.53% between 2024 and 2031.
The Fibrotic Diseases Treatment sector involves dynamics.
The market's upward path is propelled by rising healthcare spending, technological evolution, and the rising focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region set to deliver the strongest growth trajectory through the forecast period, propelled by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Fibrotic Diseases Treatment Market Snapshot
Chapter 4. Global Fibrotic Diseases Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Fibrotic Diseases Treatment Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Fibrotic Diseases Treatment Industry Trends
Chapter 5. Fibrotic Diseases Treatment Market Segmentation 1: By Treatment, Estimates & Trend Analysis
5.1. Market Share by Treatment, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Treatment:
5.2.1. Medication
5.2.2. Organ Transplantation
5.2.3. Oxygen Therapy
5.2.4. Others
Chapter 6. Fibrotic Diseases Treatment Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Applications:
6.2.1. Idiopathic Pulmonary Fibrosis
6.2.2. Hepatic Cirrhosis
6.2.3. Renal Fibrosis
6.2.4. Cutaneous Fibrosis
6.2.5. Others
Chapter 7. Fibrotic Diseases Treatment Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channels:
7.2.1. Hospital Pharmacy
7.2.2. Retail Pharmacy
7.2.3. Others
Chapter 8. Fibrotic Diseases Treatment Market Segmentation 4: By End-User Industry, Estimates & Trend Analysis
8.1. Market Share by End-User Industry, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End-User Industrys:
8.2.1. Hospitals
8.2.2. Specialty Clinics
8.2.3. Academic and Research Institutes
8.2.4. Others
Chapter 9. Fibrotic Diseases Treatment Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Fibrotic Diseases Treatment Market, Regional Snapshot 2023 & 2031
9.2. North America
9.2.1. North America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.2.3. North America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.2.4. North America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.2.5. North America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2024-2031
9.3. Europe
9.3.1. Europe Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.3.3. Europe Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.3.4. Europe Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.3.5. Europe Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2024-2031
9.4. Asia Pacific
9.4.1. Asia Pacific Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.4.3. Asia Pacific Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.4.4. Asia Pacific Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
9.4.5. Asia Pacific Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2024-2031
9.5. Latin America
9.5.1. Latin America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.5.3. Latin America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.5.4. Latin America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.5.5. Latin America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2024-2031
9.6. Middle East & Africa
9.6.1. Middle East & Africa Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.6.3. Middle East & Africa Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.6.4. Middle East & Africa Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.6.5. Middle East & Africa Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Genentech, Inc..
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Offerings
10.2.1.3. Financial PerTreatmentance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. AbbVie Inc.
10.2.3. Accord Healthcare
10.2.4. Alpine Immune Sciences
10.2.5. BellBrook Labs
10.2.6. BioMX
10.2.7. Bristol-Myers Squibb Company
10.2.8. C.H. Boehringer Ingelheim International GmbH
10.2.9. Enveda
10.2.10. Gilead Sciences, Inc.
10.2.11. Intercept Pharmaceuticals, Inc.
10.2.12. KITHER BIOTECH S.R.L.
10.2.13. Pharmaxis Ltd
10.2.14. Redx Pharma Plc
10.2.15. Sandoz International GmbH
10.2.16. Teva Pharmaceutical Industries Ltd.
10.2.17. Verona Pharma plc
10.2.18. Camber Pharmaceuticals, Inc.
10.2.19. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們